Mitochondrial single-cell ATAC-seq for high-throughput multi-omic detection of mitochondrial genotypes and chromatin accessibility
- PMID: 36792778
- PMCID: PMC10317201
- DOI: 10.1038/s41596-022-00795-3
Mitochondrial single-cell ATAC-seq for high-throughput multi-omic detection of mitochondrial genotypes and chromatin accessibility
Abstract
Natural sequence variation within mitochondrial DNA (mtDNA) contributes to human phenotypes and may serve as natural genetic markers in human cells for clonal and lineage tracing. We recently developed a single-cell multi-omic approach, called 'mitochondrial single-cell assay for transposase-accessible chromatin with sequencing' (mtscATAC-seq), enabling concomitant high-throughput mtDNA genotyping and accessible chromatin profiling. Specifically, our technique allows the mitochondrial genome-wide inference of mtDNA variant heteroplasmy along with information on cell state and accessible chromatin variation in individual cells. Leveraging somatic mtDNA mutations, our method further enables inference of clonal relationships among native ex vivo-derived human cells not amenable to genetic engineering-based clonal tracing approaches. Here, we provide a step-by-step protocol for the use of mtscATAC-seq, including various cell-processing and flow cytometry workflows, by using primary hematopoietic cells, subsequent single-cell genomic library preparation and sequencing that collectively take ~3-4 days to complete. We discuss experimental and computational data quality control metrics and considerations for the extension to other mammalian tissues. Overall, mtscATAC-seq provides a broadly applicable platform to map clonal relationships between cells in human tissues, investigate fundamental aspects of mitochondrial genetics and enable additional modes of multi-omic discovery.
© 2023. Springer Nature Limited.
Conflict of interest statement
Competing interests
The Broad Institute has filed a patent relating to the use of the technology described in this paper for which C.A.L., L.S.L., C.M., A.R. and V.G.S. are named as inventors (US Patent App. 17/251,451). A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until 31 August 2020, was a scientific advisory board member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From 1 August 2020, A.R. has been an employee of Genentech. V.G.S. serves as an advisor to and/or has equity in Novartis, Forma, Cellarity, Ensoma and Polaris Partners. A.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from Merck Research Laboratories and Allogene Therapeutics.
Figures







References
-
- Baron CS & van Oudenaarden A Unravelling cellular relationships during development and regeneration using genetic lineage tracing. Nat. Rev. Mol. Cell Biol 20, 753–765 (2019). - PubMed
-
- VanHorn S & Morris SA Next-generation lineage tracing and fate mapping to interrogate development. Dev. Cell 56, 7–21 (2021). - PubMed